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Background/aim: Psoriasis has been accepted as a systemic disease and it is known to be associated with various disorders including
metabolic syndrome. High serum uric acid levels are also associated with the components of metabolic syndrome. In this study, we
aimed to determine serum uric acid levels in patients with psoriasis and the association of uric acid levels with disease activity by taking
the presence of metabolic syndrome criteria into account, since it is one of the most important factors that affect serum uric acid levels.
Materials and methods: In this cross-sectional study, we evaluated 70 psoriasis patients and 70 healthy individuals who were matched
with the patients according to the presence of metabolic syndrome. We evaluated the demographic features, levels of serum uric acid,
Psoriasis Area Severity Index (PASI) scores, presence of psoriatic arthritis, nail involvement, and metabolic syndrome criteria of the
patients.
Results: Serum uric acid levels of psoriasis patients were significantly higher than those of controls. There was a positive correlation
between PASI scores and serum uric acid levels of the patients.
Conclusion: As hyperuricemia had a close relationship with psoriasis and PASI scores, we suggest monitoring patients with psoriasis
for serum uric acid levels during treatment and follow-up.
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1. Introduction
Psoriasis is an inflammatory and immune-mediated
papulosquamous disease with unknown etiology. It is
characterized by abnormal epidermal hyperproliferation
and differentiation, and it affects 1%–2% of the population
(1).
Uric acid is an endogenously produced end-product of
adenosine- and guanosine-based purine metabolism (2).
A number of studies showed strong correlation among
high uric acid levels, insulin resistance, and metabolic
syndrome, which has been suggested to develop secondary
to insulin resistance (3,4).
Few studies in the literature investigated serum uric
acid levels in patients with psoriasis, and those studies
reported that the levels of uric acid could be correlated with
the activity of psoriasis. However, none of those studies
evaluated metabolic syndrome, which could directly affect
the uric acid level.
Psoriasis has been accepted as a systemic disease and
it is known to be associated with various disorders such as
cardiovascular diseases, hepatosteatosis, obesity, diabetes
* Correspondence: eminettamer@yahoo.com.tr

mellitus, hypertension, and hyperlipidemia. High serum
uric acid levels are also associated with components
of metabolic syndrome such as obesity, cardiovascular
diseases, and hypertension. In our study, we aimed to
determine serum uric acid levels in patients with psoriasis
and the association of uric acid levels with disease activity
by taking the presence of metabolic syndrome into
account, since it is one of the most important factors that
affect serum uric acid levels.
2. Material and methods
Seventy patients with psoriasis aged between 17 and 82
years who were untreated for psoriasis in the previous
6 months and 70 age- and sex-matched healthy subjects
were included in this cross-sectional study. The Scientific
Research Assessment Committee of our hospital approved
the study protocol and all participants provided written
informed consent.
The demographic characteristics of the patients
such as age and sex, as well as disease characteristics
including dermatological examination, type of psoriasis,
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nail involvement, joint involvement, duration of disease,
Psoriasis Area Severity Index (PASI) score, comorbid
systemic diseases, and the treatment modalities used, were
recorded. In addition, waist circumference, fasting blood
glucose level, serum high-density lipoprotein, triglyceride
and uric acid levels, and arterial blood pressures of the
patients and controls were measured for the presence of
metabolic syndrome. The subjects that had other disorders
or had been using medications that could affect serum uric
acid levels were excluded.
PASI scores of the patients were calculated in order
to determine the clinical severity of psoriasis. CASPAR
(ClASsification criteria for Psoriatic ARthritis) criteria
were used to determine the presence of psoriatic arthritis.
The criteria of the International Diabetes Federation were
used for the diagnosis of metabolic syndrome.
The analysis of data was done with SPSS 19.0. The
intergroup differences of categorical variables were
analyzed using the chi-square test. Two groups were
compared for numerical variables using the Student t-test
when the parametric test assumptions were met, and the
Mann–Whitney U test was used when the parametric
test assumptions were not met. The linear correlation
between two numerical variables was tested with Pearson
correlation analysis when the parametric test assumptions
were met, and Spearman correlation analysis was used if
the parametric test assumptions were not met. P < 0.05
was considered statistically significant.
3. Results
The age and sex distributions of the study and the control
groups were similar (Table).
Sixteen (22.9%) of the 70 patients with psoriasis
included in the study were diagnosed with metabolic
syndrome in accordance with the criteria of the
International Diabetes Federation. Sixteen individuals
with metabolic syndrome were included in the control
group to prevent any errors while comparing the groups
for their serum uric acid levels.
The mean serum uric acid level of the study group
was 5.083 mg/dL, and this value was 4.587 mg/dL in the
control group (P = 0.030) (Table).
The mean serum uric acid level of the 54 patients
without metabolic syndrome was 4.98 mg/dL. The mean

serum uric acid level of the 54 control subjects without
metabolic syndrome was 4.02 mg/dL in the control group
(P = 0.009).
The mean serum uric acid level of the 16 patients with
metabolic syndrome was 5.42 mg/dL. The mean serum
uric acid level of the 16 control subjects with metabolic
syndrome was 5.00 mg/dL (P = 0.035).
The mean PASI score of the patients was 2.786 (range:
0.6–7.3). There was a positive and weak correlation
between PASI scores and serum uric acid levels of the
patients (Pearson correlation analysis: r = 0.425, P < 0.001).
Psoriatic arthritis was evident in 23 (32.9%) of the
70 patients included in the study. The mean serum uric
acid level was 5.052 mg/dL in the patients with psoriatic
arthritis and 5.098 mg/dL in the patients without psoriatic
arthritis (P > 0.05). Sixteen (22.9%) of the 70 patients
included in the study had psoriatic nail involvement. The
mean serum uric acid levels were 5.781 mg/dL and 4.876
mg/dL in patients with and without nail involvement,
respectively (P > 0.05).
4. Discussion
Psoriasis is a chronic inflammatory skin disease that
develops on the basis of polygenic and triggering factors.
It is currently considered as a systemic disease, and it
has been proven that it is associated with other diseases
including cardiovascular diseases, hepatosteatosis, obesity,
diabetes mellitus, hypertension, and hyperlipidemia (5,6).
A number of epidemiological studies showed that a
high serum uric acid level was an important risk factor for
development of gout, as well as for development of uric
acid nephropathy, renal failure, cardiovascular diseases,
and hypertension (3,4,7).
Kwon et al. investigated serum uric acid levels
in patients with psoriasis and they did not find any
significant difference between psoriatic patients and
controls. However, they found a significant correlation
between serum uric acid levels and PASI scores (8). In that
study, the mean age of subjects in the control group was
significantly lower compared to our study, and we suppose
that this was responsible for the different results observed
between these studies.
Increased serum uric acid levels in psoriasis have been
correlated with an accelerated epidermal turnover and

Table. Distribution of age, sex, and uric acid levels in patients and healthy subjects.
Patients (n: 70)

Controls (n: 70)

P

Females/males (n)

39/31

37/33

>0.05

Mean age, years

44.73 ± 13.31

42.24 ± 15.187

>0.05

Serum uric acid, mg/dL, mean (range)

5.08 ± 1.33 (2.3–8.3)

4.59 ± 1.26 (2.5–7.5)

0.030
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it has been reported that extensive purine breakdown
increased serum uric acid levels. Isha et al. investigated
the C-reactive protein and serum uric acid levels in
patients with psoriasis and found that serum uric acid
levels of the psoriatic patients were significantly higher
when compared to those of the controls. The authors also
reported a significant decrease in mean serum uric acid
levels after treatment of the patients for 12 weeks (9).
Gisondi et al. investigated 119 chronic plaque psoriasis
patients and 119 controls for serum uric acid levels and
found significantly higher uric acid levels in the psoriatic
patients, similar to our study. In addition, serum uric acid
levels were found significantly higher in patients with PASI
scores of >10 when compared to those with PASI scores
of <10. In our study, we found a significant correlation
between serum uric acid levels and PASI scores (10).
In 2014, Ataseven et al. investigated serum lipocalin
2, TNF receptor-1, interleukin 6, homocysteine, and uric
acid levels in psoriasis and they did not find any significant
difference between the patients and the controls for
serum uric acid levels. However, they found a significant
correlation between serum uric acid levels and PASI
(11). As Ataseven et al. mentioned in the limitations of
their study, high serum uric acid levels may be related to
components of metabolic syndrome (11). Therefore, the
effect of metabolic syndrome components should be taken
into account when investigating serum uric acid levels.
In 2001, Grzybowski et al. measured pre- and
posttreatment levels of glucose, insulin, C-peptide, and
serum uric acid levels of 12 patients with psoriasis and
determined significant reductions in serum uric acid and
fasting blood glucose levels of the psoriatic patients after
treatment (12).
Yavuzer et al. studied serum uric acid levels in 56
psoriasis patients in Turkey. The PASI scores and serum
uric acid levels were measured before treatment and
at the end of the first and second months of treatment.
While serum uric acid levels decreased significantly
at the end of the first month, there was no significant
difference in serum uric acid levels between the first and

second months of treatment. The PASI scores decreased
significantly at the end of the first month but there was
no significant difference in PASI scores between the first
and second months of treatment. Serum uric acid levels
were significantly higher in patients who were older than
38 years, who had PASI scores higher than 18, and who
had body mass index higher than 30 (13).
Many studies demonstrated associations between
serum uric acid levels and components of metabolic
syndrome including hypertriglyceridemia, obesity,
hypertension, and diabetes (4,14). Some studies in the
literature investigated serum uric acid levels in patients
with psoriasis; however, those studies did not consider
metabolic syndrome, which could affect the serum uric
acid levels directly.
It is known that metabolic syndrome is one of the
most important factors that affect serum uric acid levels;
therefore, we matched the study and control groups for
the presence of metabolic syndrome and the same number
of patients with metabolic syndrome were included in
both groups. Serum uric acid was highest in patients with
psoriasis and metabolic syndrome compared to patients
with only psoriasis or only metabolic syndrome. When
individuals with metabolic syndrome were excluded,
psoriatic patients had higher uric acid levels compared to
healthy subjects.
Psoriatic arthritis was evident in 32.9% of the
patients. However, serum uric acid levels were similar in
patients with and without psoriatic arthritis. Gisondi et
al. investigated serum uric acid levels in chronic plaque
psoriasis in 2013, and similar to our study, they did not
find any difference between patients with and without
psoriatic arthritis (10).
Our study revealed that hyperuricemia has a close
relationship with psoriasis and PASI scores. Therefore,
serum uric acid levels must be monitored in patients with
psoriasis, and particularly for those with high PASI scores,
to prevent the damaging effects of high serum uric acid
levels.
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